Gilead's remdesivir improves time to recovery for COVID-19 patients in peer-reviewed results, NIAID saysMarket Watch • 05/22/20
Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib ResultsThe Motley Fool • 05/21/20
Tread carefully if you're buying biotech stocks, traders say as group nears all-time highsCNBC • 05/21/20
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats UpZacks Investment Research • 05/19/20
Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will BeThe Motley Fool • 05/17/20
ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19GlobeNewsWire • 05/14/20